L12- Diuretics Flashcards

1
Q

PCT has (high/low) water permeability and (2) are the main drug targets / transporters

A

1- very high

2- Na+/H+ (NHE3), carbonic anhydrase, acid/base transporters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

thin descending loop of Henle has (high/low) water permeability and (2) are the main drug targets / transporters

A

1- high

2- aquaporins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

thick ascending loop of Henle has (high/low) water permeability and (2) are the main drug targets / transporters

A

1- very low

2- Na+/K+/2Cl- symporter (NKCC2)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

DCT has (high/low) water permeability and (2) are the main drug targets / transporters

A

1- very low

2- Na+/Cl- (NCC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

CT has (high/low) water permeability and (2) are the main drug targets / transporters

A

1- variable

2- ENaC, K+ channels, H+ transporters, aquaporins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

In an edematous state there is (inc/dec) NaCl reabsorption, which leads to (2) and (3). Examples that cause this include the following: (4).

A

1- inc NaCl
2- H2O retention
3- inc blood volume
4- HF, hepatic ascites, nephrotic syndrome, premenstrual edema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

list some examples of non-edematous states where diuretics may be required

A
  • HTN
  • hypercalcemia
  • diabeted insipidus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

define natriuretics and the 2 main clinical uses

A

-inhibits renal ion transported to dec Na+ reabsorption at different sites in the nephron

i) manage abnormal fluid retention (edema)
ii) treat HTN by reducing blood volume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Loop diuretics target (1) part of the nephron, acting on (2) transporter, to have (3) results.

A

(furosemide)
1- thick ascending LoH
2- inhibit NKCC2 (Na+/K+/2Cl- co-transporter)
3- inc Na, K, Cl in tubular lumen –> inc H2O excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Loop diuretic uses

A

(furosemide)

  • manages edema in HF, hepatic/renal disease
  • moderate-severe HTN
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Loop-diuretic effects on:

(1) [Ca2+]
(2) [Mg2+]
(3) PGs
(4) renal vascular resistance
(5) renal blood flow

A
(furosemide)
1- inc Ca excretion
2- inc Mg excretion
3- inc PG synthesis
4- dec resistance
5- inc RBF
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Loop diuretics are given in (1) fashion and have a (2) half-life

A

(furosemide)
1- orally, paraenterally
2- 2-4 hrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

loop diuretics have the following adverse effects

A

(furosemide)

  • ototoxicity
  • hyperuricemia
  • acute hypovolemia
  • hypokalemia
  • hypomagnesemia
  • allergic reactions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Loop Diuretics:

(1) dec urinary excretion of….
(2) inc urinary excretion of….

A

(furosemide)
1- dec uric acid excretion

2- inc Na, K, Mg, Ca, urine volume excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Thiazides target (1) part of the nephron, acting on (2) transporter, to have (3) results.

A

1- DCT
2- inhibits NCCT (Na+/Cl- co-transporter)
3- inc Na, Cl in tubular lumen –> inc H2O excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Thiazide uses (hint: 5)

A
  • HTN (alone or in combination)
  • HF (mild-moderate)
  • hypercalciuria (inhibits Ca excretion, used for kidney stones)
  • Diabetes Insipidus (=> hyperosmolar urine)
  • premenstrual edema
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Thiazide effects on:

(1) [K+]
(2) [Mg2+]
(3) [Na+ / Cl-]
(4) [Ca+]
(5) PVR

A
1- inc K excretion
2- inc Mg excretion
3- inc Na/Cl excretion
4- dec Ca excretion
5- dec peripheral vascular resistance (dec blood volume- which will recover although hypotensive effects remain)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Thiazides are given in (1) fashion and have a (2) half-life

A

1- orally

2- 40 hrs (1-3 wks for stable effects)

19
Q

list the thiazides

A
  • HCTZ
  • Chlorthalidone
  • Metolazone
20
Q

thiazides should replace loop-diuretics in the what condition

A

moderate to severe CKD (GFR < 30 mL/min)

21
Q

(1) thiazide has the longest duration of action

(2) is the most potent thiazide

A

1- chlorthalidone (40-60 hr half life, used qd for HTN)

2- metolazone (–> Na excretion in advance of kidney failure)

22
Q

thiazides have the following adverse effects

A
  • hypokalemia, hyponatremia
  • hyperuricemia, hyperglycemia, hyperlipidemia
  • hypersensitivity
  • sexual dysfunction
23
Q

Thiazides:

(1) dec urinary excretion of….
(2) inc urinary excretion of….

A

1- dec uric acid, Ca excretion

2- inc K, Na, Mg, urine volume excretion

24
Q

list the K+-sparing diuretics (include categories)

A

Aldosterone antagonists: Spironolactone, Eplerenone

Na+ channel inhibitors: Triamteren, Amiloride

25
K+-sparing diuretics (Spironolactone, Eplerenone) target (1) part of the nephron, acting as (2), to have (3) results.
1- CT 2- aldosterone antagonists 3- prevents ENaC (Na in) and ROMK (K out) transporters on lumenal side --> dec Na reabsorption, dec K excretion
26
K+ sparing diuretic (Spironolactone, Eplerenone) uses
- HF (adjunct, to prevent cardiac remodeling) - HTN (adjunct) - primary hyperaldoteronism (for Dx and Tx, only time it is used alone) - edema (associated with excess aldosterone)
27
K+ sparing diuretics (Spironolactone, Eplerenone) have the following adverse effects
- gastric upset / peptic ulcers - endocrine effects (antiandrogen) - hyperkalemia - nausea, lethargy, mental confusion (rare)
28
____ must be monitored in patients using K+-sparing diuretics (Spironolactone, Eplerenone)
potassium levels
29
K+-sparing diuretics (Triamteren, Amiloride) target (1) part of the nephron, acting as (2), to have (3) results.
1- CT 2- ENaC (Na+ channel) inhibitors 3- dec Na+/K+ exchange --> inc Na+ in lumen --> inc H2O excretion, dec Na reabsorption, dec K excretion
30
K+ sparing diuretics (Triamteren, Amiloride) have the following adverse effects
- hyperkalemia - hyponatremia - leg cramps - GI upset - dizziness, pruritus, HA, minor visual changes
31
K+ sparing diuretics (all): (1) dec urinary excretion of.... (2) inc urinary excretion of....
1- dec K excretion | 2- inc Na, urine volume excretion
32
Carbonic Anhydrase inhibitors target (1) part of the nephron, acting as (2), to have (3) results.
(acetazolamide) 1- PCT 2- CA inhibitor --> inc HCO3- and Na excretion 3- dec Na+/H+ exchange (basolateral side, Na in, H out) --> dec Na+/K+ ATPase (apical side, Na out, K in) --> more Na+ and HCO3- in the lumen --> more alkaline urine + inc volume
33
CA inhibitor uses
(acetazolamide) - glaucoma - epilepsy (alone or with other antiepileptics) - mountain sickness prophalaxis - metabolic alkalosis
34
CA inhibitors are given in (1) fashion and have a (2) half-life
(acetazolamide) 1- oral (well absorbed) or IV (acute Tx for closed angle glaucoma) 2- 3-6 hrs
35
CA inhibitors adverse effects
(acetazolamide) - hyponatremia, hypokalemia - crystalluria (due to inc HCO3 in urine) - metabolic acidosis --> malaise, fatigue, depression, HA, GI upset, drowsiness, paresthesia
36
CA inhibitors: (1) dec urinary excretion of.... (2) inc urinary excretion of....
(acetazolamide) 1- n/a 2- HCO3-, Na, K, urine volume
37
osmotic diuretics target (1) part of the nephron, acting as (2), to have (3) results.
(mannitol) 1- everywhere (no specific targets) 2- osmotic agent (inc plasma osmolarity) 3- H2O pulled out of body tissues --> inc urine volume
38
osmotic diuretic uses
(mannitol) - inc urine flow in patients with acute renal failure - reduce intracranial pressure -- treats cerebral edema - promote excretion of toxic substances
39
osmotic diuretics are given in _____ fashion
(mannitol) | IV due to poor GI absorption
40
osmotic diuretics adverse effects and contraindications
(mannitol) - ECW expansion => hyponatremia - tissue dehydration -not used in CHF, pulmonary embolism
41
ADH antagonists target (1) part of the nephron, acting as (2), to have (3) results.
(conivaptan) 1- CT 2- V1/V2 receptor antagonist (normally bind ADH) 3- dec H2O permeability --> dec retention and inc urine volume (dilute urine)
42
ADH antagonist uses
(conivaptan) - euvolemic and hypervolemic hyponatremia - SIADH - HF (if benefits >>> risks, safety not established)
43
ADH antagonists are given in _____ fashion
(conivaptan) IV only -metabolized by and potent inhibitor of CYP3A4
44
ADH antagonists adverse effects and contraindications
(conivaptan) - infusion site rxns - thirst - AFib - GI, electrolyte disturbances - nephrogenic diabetes insipidus -Not used in renal failure, hypovolemic hyponatremia